Hefei Lifeon Pharmaceutical (SZ:003020) Shanxi Securities·2025-05-30 03:23Investment Rating - The report upgrades the investment rating for the company to "Buy-B" [5][12]. Core Views - The company is expected to see a turnaround in performance due to the clearance of centralized procurement risks and the approval of the methylphenidate three-layer chip, which is anticipated to significantly boost revenue [6][12]. - The company reported a revenue of 1.518 billion yuan in 2024, a year-on-year decline of 20.11%, with a net profit of 161 million yuan, down 29.15% [6][12]. - In Q1 2025, the company achieved a revenue of 360 million yuan, a year-on-year increase of 7.98%, and a net profit of 38 million yuan, up 25.94% [6][12]. Financial Performance - The company’s gross margin improved to 69.16%, an increase of 17.68 percentage points year-on-year, while the net profit margin remained stable at 9.87% [6][12]. - The projected revenues for 2025, 2026, and 2027 are 1.919 billion yuan, 2.404 billion yuan, and 2.988 billion yuan, respectively, with corresponding net profits of 212 million yuan, 281 million yuan, and 370 million yuan [12][14]. - The earnings per share (EPS) are expected to be 1.11 yuan, 1.47 yuan, and 1.94 yuan for the years 2025, 2026, and 2027, respectively [12][14]. Market Dynamics - The company has seen significant growth in its industrial business, with an 18.92% increase in revenue, driven by the successful launch of several products [8][9]. - The approval of the methylphenidate three-layer chip is expected to open up a large market opportunity, with an estimated 23 million children and adolescents affected by ADHD in China [9][12]. - The company has established a strong position in the market with its proprietary controlled-release technology, which is a key competitive advantage [9][11].